Just another WordPress site

Category: News Releases

  • Response Biomedical Corp. Announces Strategic Collaboration with Sugentech, Inc. to Expand in High Growth Global Markets

    • Provides scalable, decentralized, rapid response testing solutions to enable global expansion.
    • Accelerates expansion into the chronic disease diagnostics market—a large, high-growth, global opportunity—by enabling additional assay development for long-term clinical indications.
    • Creates synergies for sustained breakthrough innovation by combining Sugentech’s cutting edge technology with Response’s rapid response and commercialization capabilities, to support a pipeline of new tests and faster time-to-market globally.

    Vancouver, Canada, [March 24, 2026] — Response Biomedical Corp. (Response), a leader in acute care diagnostics, today announced a strategic collaboration with Sugentech, Inc. (Sugentech, KOSDAQ: 253840) to support the advancement and commercialization of a next generation rapid response diagnostic platform for global markets.

    Sugentech is a South Korea–based IVD company that develops next-generation in-vitro diagnostic products by combining biological technology and information technology, bringing diagnostic system expertise that complements Response’s experience in market development and commercialization of acute care near patient testing solutions. The collaboration reflects a shared focus on expanding access to high value diagnostic solutions in regions where decentralized or rapid response testing is increasingly essential to timely clinical decision-making. 

    “This collaboration is a natural fit for both organizations,” said Taso Tsonis, Interim CEO, Response Biomedical. “By bringing our strengths together, we can deliver scalable solutions that help clinicians make faster, more confident decisions in decentralized settings.” 

    “By combining the deep R&D expertise and extensive industry experience that both companies have built over many years in the point-of-care diagnostics field, we expect this collaboration to generate strong synergies and accelerate our expansion into global markets.” said Dr. Mi-Jin Sohn, CEO, Sugentech

    By combining Sugentech’s advanced point-of-care technology with Response’s established commercial reach, we are uniquely positioned to expand our global footprint and accelerate the launch of innovative diagnostic solutions. Together, we enable patient care across the full continuum—from the pharmacy to the laboratory and every point in between. These complementary strengths create a compelling growth trajectory, unlocking new market opportunities and delivering meaningful healthcare impact and long-term value for our stakeholders.

  • RAMP COVID-19 antigen test gets Health Canada approval

    Response Biomedical’s RAMP COVID-19 antigen test gets Health Canada approval.

    Response Biomedical Corp. (Response), a global provider of acute care diagnostic testing solutions, is announcing today that Health Canada has granted the RAMP® COVID-19 Antigen Test authorization to commercialize under the Emergency Use Interim Order. The Health Canada authorization allows Response to market and sell the RAMP® COVID-19 Antigen Test to countries that recognize Health Canada authorization.

    The RAMP® COVID-19 Antigen Test uses the RAMP® 200 instrument for the detection of SARS-CoV-2 nucleoproteins in nasal swabs from individuals who are suspected of having COVID-19 infection within the first 5 days of symptom onset. The results are delivered in 15 minutes, enabling timely decision-making for healthcare professionals and on-site identification of COVID-19. The test kit contains all required components, including the nasal swabs, to allow for the rapid triage of individuals suspected of SARS-CoV-2 infection.

    The RAMP® instrument is a small, automated system capable of storing and transmitting results digitally. The RAMP 200 offers complete traceability and reportability with the flexibility of running one to six tests at a time. 

    “As a global provider of acute care tests, it was imperative for us to join the fight against the pandemic for Canada. The addition of the COVID-19 Antigen Test on our RAMP platform completes our panel of tests that have been used globally in the fight against COVID-19 since the start of the pandemic.” stated Dr. Barb Kinnaird, CEO of Response.

    “At the onset of the pandemic, NGen mobilized funding to support made-in-Canada solutions to combat COVID-19,” said Jay Myers, CEO, NGen. “We are pleased to see that Response Biomedical’s RAMP COVID-19 antigen test has been recognized by Health Canada as a critical tool in our arsenal to protect the health and well-being of Canadians.”

    Health Canada’s decision is under Health Canada’s expedited authorization pathway, Interim Order No. 3. As a part of the authorization process, clinical data gathered from prospective clinical studies were included in support of the RAMP COVID-19 Antigen test performance against recognized PCR lab-based tests. The test was developed with advisory support and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

    About Response Biomedical Corporation

    Response Biomedical Corp. (Response) is a Canadian manufacturer and global supplier of diagnostic tools that aid in the diagnosis of life-threatening diseases. Response focuses on providing lab quality results in minutes and our RAMP® technology delivers a total solution for making better, faster decisions. RAMP® tests are commercially available to aid in the diagnosis of heart attack, congestive heart failure, sepsis, pregnancy and more. The company is passionate about the patient’s experience and our core purpose to save lives globally. For more information about Response, visit www.responsebio.com.

  • RAMP COVID-19 Antigen Test Gets CE Mark

    RAMP COVID-19 Antigen Test Gets CE Mark

    Response Biomedical launches COVID-19 (SARS-CoV-2) antigen test for countries accepting CE mark, to support the growing demand for testing.

    Response Biomedical Corp. (Response), a global provider of acute care diagnostic testing solutions, announced today the launch of the RAMP® COVID-19 Antigen Test in countries that require CE marking. The CE Mark allows Response to market and sell the RAMP® COVID-19 Antigen Test to countries that recognize CE marking.

    “The addition of the COVID-19 Antigen Test on the RAMP platform enhances our current offering of acute care tests that are already being used in the fight against COVID-19”, stated Dr. Barb Kinnaird, CEO of Response Biomedical. “We continue to be part of the global efforts against the pandemic and have scaled our manufacturing to cater to the ongoing growing demand for the acute care tests sold on our platform world-wide.”

    The RAMP® instrument is a small, automated system capable of storing and transmitting results digitally. The RAMP® 200 offers complete traceability and reportability with the flexibility of running one to six tests at a time. In a method comparison study of 158 volunteers, the RAMP® COVID-19 Antigen Test showed 95% concordance with the leading U.S. antigen test.

    The RAMP® COVID-19 Antigen Test uses the RAMP® 200 instrument for the detection of SARS-CoV-2 nucleoproteins in nasal swabs from individuals who are suspected of having COVID-19. The results are delivered in 15 minutes, enabling timely decision-making for healthcare professionals and on-site identification of COVID-19. The assay kit contains all components, including the swabs, allowing rapid triage of individuals suspected of SARS-CoV-2 infection.

    About Response Biomedical Corporation

    Response Biomedical Corp. (Response) is a Canadian manufacturer and global supplier of diagnostic tools that aid in the diagnosis of life-threatening diseases. Response focuses on providing lab quality results in minutes and our RAMP® technology delivers a total solution for making better, faster decisions. RAMP® tests are commercially available for the aid in early detection of heart attack, congestive heart failure, sepsis, thromboembolism, and pregnancy. The company is passionate about the patient’s experience and our core purpose to improve and save lives globally. For more information about Response, visit www.responsebio.com.

  • RAMP Education and Development – Learning Management System

    RAMP Education and Development – Learning Management System

    In order to provide our channel partners with the highest level of support and education, Response Biomedical Corp. recently implemented the RAMP Education And Development (READ) program. READ is an online learning platform where our channel partner’s sales and application teams can learn more about RAMP clinical tests, the conditions they diagnose, RAMP technology, and the competitive advantages of RAMP.

    The RAMP platform offers an essential acute care menu. To achieve Response Biomedical’s goal of saving as many human lives as possible, our partners need to be armed with the most recent and relevant clinical information. For this reason, we will frequently be updating our course material and releasing new content.

    The advantage of utilizing an online learning platform is that our partners can learn on their own schedule and at their own pace. There are learning checks in place to ensure that the most critical information is being retained by the learner. The READ program also offers downloadable resources that are beneficial tools to use when approaching current or potential customers.

    Please contact us if you would like to learn more about READ program today.